



# MIT Open Access Articles

## *Functionalizing the Tumor Microenvironment with Microfluidics for Anti-cancer Drug Development*

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

<b>Citation</b>	Shang, Menglin et al. "Functionalizing the Tumor Microenvironment with Microfluidics for Anti-cancer Drug Development." Lab on a Chip 19, 3 (January 2019): 369-386 © 2019 The Royal Society of Chemistry
<b>As Published</b>	<a href="http://dx.doi.org/10.1039/c8lc00970h">http://dx.doi.org/10.1039/c8lc00970h</a>
<b>Publisher</b>	Royal Society of Chemistry (RSC)
<b>Version</b>	Author's final manuscript
<b>Citable link</b>	<a href="https://hdl.handle.net/1721.1/122464">https://hdl.handle.net/1721.1/122464</a>
<b>Terms of Use</b>	Creative Commons Attribution-Noncommercial-Share Alike
<b>Detailed Terms</b>	<a href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</a>



# MIT Open Access Articles

## *Functionalizing the Tumor Microenvironment with Microfluidics for Anti-cancer Drug Development*

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

<b>Citation</b>	Shang, Menglin et al. "Functionalizing the Tumor Microenvironment with Microfluidics for Anti-cancer Drug Development." Lab on a Chip 19, 3 (January 2019): 369-386 © 2019 The Royal Society of Chemistry
<b>As Published</b>	<a href="http://dx.doi.org/10.1039/c8lc00970h">http://dx.doi.org/10.1039/c8lc00970h</a>
<b>Publisher</b>	Royal Society of Chemistry (RSC)
<b>Version</b>	Author's final manuscript
<b>Citable link</b>	<a href="https://hdl.handle.net/1721.1/122464">https://hdl.handle.net/1721.1/122464</a>
<b>Terms of Use</b>	Creative Commons Attribution-Noncommercial-Share Alike
<b>Detailed Terms</b>	<a href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</a>

# Functionalizing the Tumor Microenvironment with Microfluidics for Anti-cancer Drug Development

Menglin Shang<sup>1,3</sup>, Ren Hao Soon<sup>3</sup>, Chwee Teck Lim<sup>1,2,3,4,5\*</sup>, Bee Luan Khoo<sup>1\*</sup>, Jongyoon Han<sup>1,4,6\*</sup>

<sup>1</sup>BioSystems and Micromechanics (BioSyM) IRG, Singapore-MIT Alliance for Research and Technology (SMART) Centre, Singapore

<sup>2</sup>Mechanobiology Institute, National University of Singapore, Singapore

<sup>3</sup>Department of Biomedical Engineering, National University of Singapore, 7 Engineering Drive 1, Singapore 117574

<sup>4</sup>Department of Mechanical Engineering, National University of Singapore, Singapore

<sup>5</sup>Biomedical Institute for Global Health Research and Technology, National University of Singapore, Singapore

<sup>6</sup>Department of Electrical Engineering and Computer Science, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

\* Contact:

Jongyoon Han ([jyhan@mit.edu](mailto: jyhan@mit.edu))

Room 36-841, Research Laboratory of Electronics,

Massachusetts Institute of Technology

77 Massachusetts Avenue, Cambridge, MA 02139, USA

Bee Luan Khoo ([beeluan@smart.mit.edu](mailto: beeluan@smart.mit.edu))

Singapore-MIT Alliance for Research & Technology

1, Create Way, Enterprise Wing, Singapore 138602

Chwee Teck Lim ([ctkim@nus.edu.sg](mailto: ctkim@nus.edu.sg))

Department of Biomedical Engineering, National University of Singapore,

9 Engineering Drive 1, Singapore 117575, Singapore

## Abstract

Cancer is the leading cause of death worldwide. The complex and disorganized tumor microenvironment makes it very difficult to treat this disease. The most common *in vitro* drug screening method now is based on 2D culture which poorly represents actual tumors. Therefore, many 3D tumor models which are more physiologically relevant, have been developed to conduct *in vitro* drug screening and alleviate this situation. Among all these methods, microfluidic tumor model has the unique advantage of recapitulating tumor microenvironment in a comparatively easier and representative fashion. While there are many review papers available on the related topic of microfluidic tumor model, in this review we aim to focus more on the possibility of generating “clinically actionable information” from these microfluidic systems, besides scientific insight. Our topics cover the tumor microenvironment, conventional 2D and 3D cultures, animal model, and microfluidic tumor model, emphasizing their link to anti-cancer drug discovery and personalized medicine. We hope it can guide new researchers into this area to find their direction as well as showcase recent progress to readers of interest.


**KEYWORDS** Tumor-On-Chip, Cancer, Drug Discovery, Personalized Medicine, Tumor Model, Microfluidics, Three Dimensional Models

## 1. Introduction

Cancer is the second leading cause of death in the world, in both developed countries and less developed countries [1]. According to data published in GLOBOCAN by the IARC, there were an estimated 14.1 million new cases and 8.2 million deaths worldwide in 2012, which made cancer the second leading cause of death globally [2]. One of the primary reasons for the high mortality rate of cancer is due to cancer metastasis; the process where tumor cells acquire the ability to intravasate into the nearby blood or lymphatic system, travel through the circulatory system and extravasate to other parts of the patient [3]. Studies have estimated that 90% of deaths for patients with solid tumors can be attributed to metastasis [4, 5]. Over the years, research has demonstrated that the tumor microenvironment plays a key role in this process [3, 6, 7]. Specifically, the tumor microenvironment has also been shown to induce tumor heterogeneity and promote the growth of a tumor itself [8, 9].

To understand the underlying mechanisms through which the tumor microenvironment impacts cancer progression and prognosis, researchers have been trying to create a model that can more accurately represent the *in vivo* tumor microenvironment. There is much value in doing so because the tumor heterogeneity confers unique advantages for the tumor, such as an inherent resistance to therapy [10, 11]. Since different sub-populations of a tumor can respond differently to therapy, this makes it difficult for clinicians to treat cancer effectively. This heterogeneity for cancer can be further broken down into two sub-categories, intra-tumor and inter-tumor. Both categories of heterogeneity refer to different subpopulations of existing cancer cells. Intra-tumor refers to cancer cells within a tumor while inter-tumor heterogeneity refers to cancer cells between different tumors, tumors of different tissue types or between patients who are afflicted with the same cancer type. Such heterogeneity is observed in the cohort of circulating tumor cells (CTCs) [12, 13], which can be isolated from the peripheral bloodstream or cultured for further analyses. The exact mechanism through which tumor heterogeneity can be attributed to, cancer stem cells or clonal evolution, is still under debate. However, this heterogeneity will manifest both chemically and biologically which will then give rise to genetic and phenotypic variations seen in tumors.

Most current reviews either focus on specific fields such as cell migration and 3D cell culture or highlight the biological applications of *in vitro* tumor models [14-16], with limited emphasis on their contribution to anti-cancer drug screening and development. This review aims to provide readers with a detailed discussion on the current state-of-art microfluidics-based tumor models, with a special focus on their application in anti-cancer drug screening and the engineering approaches to recapitulate the tumor microenvironment (**Figure 1**). First, we provide a broad overview of the tumor microenvironment in terms of its physical, chemical and biological composition, to enable readers to better understand the underlying design principles behind tumor-on-a-chip models. Next, we look at the non-microfluidic tumor models which have been developed. Lastly, we discuss the tremendous potential of microfluidic tumor models and its ability to replicate the tumor microenvironment in a physiologically relevant manner which is comparatively easier to implement. Through the development of an *in vitro* model which can accurately represent the *in vivo* conditions of the tumor microenvironment, this would help not only researchers develop better drugs but could also pave the way for clinicians to personalize cancer therapy for individuals.



**Figure 1: Overview of this review.** Schematics showing how microfluidics can play a critical role in capturing the essence of the tumor niche: from replicating complex vasculature architecture, co-culturing of various cells to mimicking cell-cell interactions more accurately. Others include *in vitro* models to mimic the shear stress, pressure or biophysical and biochemical gradients which the tumor is exposed to.


## 2. Tumor microenvironment

On a macroscopic level, the solid tumor microenvironment is very similar to that of an organ, where it comprises specialized cells being sustained by blood vessels, with each performing a different role in a tumor [17]. For instance, apart from the malignant cells, the tumor microenvironment also includes several different immune cell types, cells from blood vessels (pericytes and adipocytes) and fibroblasts, each interacting and exhibiting dependencies on each other. As a result, solid tumors are inherently heterogeneous and structurally complex [18].

The major component of any cellular microenvironment is the extracellular matrix (ECM) (**Figure 2**). Beyond providing structural support, the ECM also plays an important role in the architecture. The ECM is known to influence cell behavior in terms of cell migration, and anchorage, by serving as a medium to transmit external forces from environmental cues and even cell signaling throughout the entire lifespan of the cell and at critical phases in their lives [19, 20]. The ECM is composed of a large collection of biochemically distinct components including proteins, glycoproteins, proteoglycans, and polysaccharides [21, 22]. When these components are placed in a specific arrangement, they grant the cells which adhere to it via the focal adhesion points various biochemical, biomechanical and physical properties. As the ECM plays a part in almost all cellular behavior and is indispensable to all cells, it is always tightly regulated.

However, in the ECM of a tumor niche, changes in the amount, composition or topography of the ECM can lead to changes in the properties of the ECM itself. For instance, various collagens, including collagen I, II, III, V, and IX, have increased deposition rates during tumor formation [23-25]. The overexpression of these collagens leads to the formation of a stiffer ECM which

in turn promotes the formation of a tumorigenic microenvironment [26]. By doing so, cell growth is enhanced by stiffening and cell-cell junction integrity is compromised, impeding lumen formation. Over time, non-polarized, disorganized and invasive colonies that lack cell-cell junction proteins with irregular cell shapes are formed, which is one of the hallmarks of cancer [3].



**Figure 2: Overview of the tumor microenvironment.** Cells in the tumor microenvironment comprising different subpopulations of cancer cells, lymphocytes, and macrophages. This makes it a highly complex environment with each element exhibiting some form of dependency on the other, of which only a few are illustrated. (a) Diagram of the blood vessel in a tumor with gaps indicating leakiness in the blood vessel. This, coupled with the fact that a tumor is typically larger in size than healthy tissues, leads to the formation of hypoxic regions. (b) Hypoxia then results in a cascade of events which is initiated when the secretion or breakdown of various growth factors is disrupted [25-29].

Apart from physical changes, chemical changes within the niche will also occur. A prominent example is represented by the hypoxia-inducible factor-1 (HIF-1), a type of transcription factor, which response to a decrease in available oxygen in the cell. HIF-1 is always present in healthy cells and degrades rapidly under normoxia by the von-Hippel-Lindau (VHL) tumor suppressor protein in normal tissues [27]. However, due to the enlarged size of a tumor when the cells start multiplying uncontrollably, some cells especially those near the periphery of a tumor do not have access to a blood vessel. As a result, these cells enter a state of hypoxia and HIF-1 rapidly accumulates as VHL is unable to break it down. This increased expression of HIF-1 has also been demonstrated to drive angiogenesis by promoting the formation of vessels in the tumor microenvironment through the upregulation of the vascular endothelial growth factor (VEGF) protein [28]. While the hypoxic conditions in a tumor may be thought to be alleviated with the formation of new blood vessels, this is not the case. In fact, the hypoxic conditions in a tumor are further exacerbated as the newly formed vessels are leakier and more dilated (**Figure 2a**). This further reduces the ability of the vascular system to deliver blood into a tumor [29]. As VEGF is also a form of chemoattractant, the hypoxic regions in a tumor will also be associated with a substantial increase in the number tumor-associated macrophages (TAMs) of up to 50% of the cell tumor mass (**Figure 2b**) [30, 31]. It is important to note here that the upregulation of VEGF is only one of the pathways through which angiogenesis is induced. Alternatively, through the expression of oncogenes such as such *Ras* or *Myc* inside tumor cells, angiogenesis can also be induced in a tumor. Moreover, VEGF is expressed in varying quantities within a tumor. As the expression of VEGF promotes neo-vascularization in tumors, this results in a network of blood vessels within a tumor which cannot be replicated or predicted easily, thereby making the tumor microenvironment highly complex.

Apart from changes in a tumor which are driven by external cues, biological changes can also be induced by changes in the DNA. For instance, a missense mutation in the p53 transcription factor, which can be held accountable for tumor initiation, development, and growth in more than half of solid tumor cancers [32]. Briefly, the p53 protein acts as a tumor suppressor as it induces apoptosis when cellular mutations occur and initiate DNA repairs in healthy cells [32]. However, when mutations occur in the p53 protein, in addition to the loss of tumor-suppressing functions of the cell, many of these mutations also cause active promotion of tumor development indirectly. This is because the mutation changes the DNA binding ability of the protein. Consequently, this affects the ability of the protein to interact with other proteins or transcription factors [33]. When the effects of all these aberrations in a tumor are added together, the resultant is a highly heterogeneous tumor. This can be explained by how the regional differences in a tumor arising from chemical and biological aspects of the niche will result in changes in the physical aspect of the niche. For instance, leaky blood vessels developed in a tumor will give rise to different sub-populations of cancer cells within a tumor as different hypoxic and pressure differences will be created in the niche (**Figure 2**). Due to this difference, the cells in a tumor respond differently to these cues and in the process, creates tumor heterogeneity. Hence, it is imperative that researchers create a suitable tumor model. A brief introduction to these models will be given in the following section.

### 3. Non-microfluidic tumor models

Over the past two decades, many models have been created to mimic this microenvironment and various techniques involving small animal models or two-dimensional (2D) *in vitro* cancer models have been developed for drug testing and screening [34, 35]. Broadly, these methods can be grouped into three main classes: tumor tissue explant, animal-based models, and cell

line-based tumor models. A short introduction to the first two methods will be included in this section, together with a discussion of the key advantages and disadvantages.

Tumor tissue explants are the most direct and rudimentary form of culturing tumors. In this procedure, the tumor is first removed from the patient after a solid biopsy is performed. The extracted tumor is then processed by removing the necrotic parts before it is then cut into small pieces and washed with cell media. The tumor is then seeded into collagen gel which has been pre-embedded on a culture dish and then cultured. As explants utilise similar techniques and equipment as those used in conventional cell culture work, this makes it easy for researchers to adopt tumor tissue explants in their research [36, 37]. Moreover, since the tumor explant is derived from the original patient sample, the tumor architecture is largely preserved, making this a representative model. Conversely, the reproducibility of a tumor also becomes an issue since a tumor is highly heterogeneous and varies not only between patients but also between different tumors or even within the same tumor inside an individual patient [38]. This implies that once the tumor explant has been used in an experiment, it may almost be impossible to obtain another explant with the same features to test the repeatability of the results.

There are also animal-based models which have been developed. Animal-based models typically involve mouse models. In this, two sub-types of mice are typically used: transgenic mice carrying cloned oncogenes or knockout mice lacking tumor suppressor genes. Even though a tumor is essentially being cultivated in a surrogate human model, this method has demonstrated some success over the years such as the discovery of APC gene suppression which initiates tumor formation in an animal mouse model of human familial adenomatous polyposis [39]. As a tumor will be cultivated *in vivo* within these animals, it is also able to better mimic the molecular and histopathological features of cancer [40, 41]. Indeed, this has made mouse models highly popular with researchers (65% of 949 oncology papers published in 2016 utilized a mouse tumor model [42]). However, as mice can tolerate higher drug concentrations than human patients, questions about their effectiveness in using them for drug tests will remain even if a representative 3D model is to be created. As such, to further improve on animal-based models, other animals such as dogs and cats have been increasingly used in the search for new cancer treatments. These animals are selected because they possess genes which are more like humans than mouse genes. Studies conducted in recent years have demonstrated that the same tumor oncogenes and suppressor genes contribute to the development of cancer in humans and dogs [43]. Major molecular targets such as PTEN, BRAC1 or p53 have demonstrated sequencing identities that are more similar to humans as compared to those from a mouse, thereby indicating that a more accurate model can potentially be established [34]. However, for all the benefits that an animal-based model confers, they still have underlying ethical issues and have very strict regulations regarding the use of them which restricts their use to only very specific purposes such as in a drug test. With increasing recognition of this problem such as the report set out by the National Research Council (US) [44], the conventional position that animals can be used as they are not sentient is now weakened. Moreover, it is important to note that successful translation from animal models to clinical cancer trials only stand at 8% [45]. This discrepancy may be attributed to a variety of reasons ranging from the tangible, such as the lack of a standardized protocol for animal testing unlike in human trials [42], to the intangible such as how stress experienced in mice has been demonstrated to have a substantial impact on the experimental results [46]. It is for these reasons that researchers seek to build tumor models using methods which have a higher throughput and less batch-to-batch variation than those mentioned above.

### **3.1 Two-dimensional models**



In *2D* models, the cells are typically cultured and grown as a monolayer on flat surfaces such as in cell culture flasks or wells. Here, the cell culture can be performed either as a monoculture or as co-culture with different cell types. While monocultures are well-established methods of culturing cells in an *ex vivo* environment and are optimal for obtaining cells, which are of the same phenotype, monocultures are typically not used in tumor models because they are too simple. Given that a tumor comprises various cell types, the resulting cell-cell communication and interaction cannot be replicated in a culture consisting of only a single cell type. Furthermore, these interactions cannot be ignored as they could lead to a cascade of whole other events. For instance, cancer metastasis which is the leading cause of death in cancer patients occurs through a series of mechanisms (most prominently the epithelial to mesenchymal transition [EMT]). EMT is initiated when the cells lose adhesion and polarization while acquiring migratory properties as part of its interaction with other cells in a tumor [47]. As a result, monocultures are inherently limited in what they can achieve in terms of creating a suitable environment for researchers to study the tumor.

Techniques which involve co-culturing of cells have been developed in order to overcome this limitation. Co-cultures, as the name suggests, comprises two or more monocultures of cells in a single culture dish or well. Fundamentally, co-cultures are very similar to monocultures in terms of how they are both still *2D* cultures which can be cultured with similar experimental techniques. This provides researchers with a quick, simple and reliable way to understand the interactions between cells. For example, by studying the genetic alterations in the tumor cells, the events through which the stroma affects cancer cells can be elucidated [48]. Co-cultures are typically achieved via two methods: direct or indirect. In a direct co-culture, the cells are layered on top of one another and are in physical contact with each other. However, in an indirect co-culture, the cells are cultured using well-inserts [49]. In the former, due to the physical contact between cells, this allows for the study of adhesion molecules such as N-cadherins [50]. In the latter, signaling pathways between the different types of cells such as cancer cells and fibroblasts can be better studied [51]. In general, there is a need to ensure that the cells of the co-culture require similar media and that extra care must be taken during the cell culture, such as the need to seed one cell type at a time in order to improve on reliability. However, the main advantage is that the *2D* co-culture model offers a quick and simple method to mimic specific aspects of the tumor microenvironment.

Although *2D* monolayers of cells can be successfully cultivated on cell culture plates and serve as a method for researchers to study various aspects of the tumor environment in detail, *2D* monolayers are still found to be lacking. For instance, *2D* models cannot be used in the testing of drug efficacy as previous studies have shown that the efficacy still varies quite substantially between *in vivo* as compared to *2D* monoculture [52, 53]. This may be attributed to how *2D* layers are still spatially irrelevant given that actual tumors are *3D* in nature. Specifically, the location of focal adhesions and the various cell surface proteins such as integrin and their binding has been demonstrated to be markedly different from their original *3D* form [54, 55]. Furthermore, *2D* cultured cells are artificially polarized when their cytoskeleton rearranges as they are stretched on the culture plate, which in turn causes these cultured cells to express genes and proteins which are atypical [56]. Hence, there is a need for *3D* models in order to obtain more information such as drug penetration or to aid in understanding the tumor niche better. Given the different benefits and drawbacks of the two models (*2D* vs. *3D*), one should first understand what questions need to be addressed in order to pick the most appropriate model.

### **3.2 Three-dimensional models**

Conventional *in vitro* culture methods could also generate three-dimensional tumor structure which is more physiologically relevant than 2D models and more cost-efficient than animal models [57]. These methods can be divided into four categories: suspension culture, non-adherent surface methods, hanging drop methods, and scaffold-based culture.

Suspension culture prompts aggregate formation by agitating fluid and preventing cells from adhering to container surface [58]. There are mainly two types of approaches to keep cells suspending in the culture medium. One is to use a stirrer, like a spinner flask bioreactors [59-61]. The other approach is to rotate the container wall. Representative devices are rotary cell culture system [62, 63]. Suspension culture generally has high throughput but lack the ability to control the size and uniformity of the spheroids formed [64, 65].

Instead of agitating fluid, the non-adherent surface method prevents cell adherence to the container surface and promotes spheroid formation directly through the use of antifouling surface coatings [66]. Many different material coatings, such as agarose, poly-HEMA and pluronic acid coatings have been proved to work well in forming viable cellular spheroids [67-70]. Although the size of spheroids generated using this method varies in a large range, this problem can be overcome by using microarrays instead [66].

Hanging drop methods force suspended cells to aggregate and then develop into regular and tight spheroids at the bottom of small hanging droplets (typically 20 $\mu$ l) [71]. The hanging drops are generated at the underside of a flat surface as a result of surface tension and gravity [66]. This technique has been widely used in cancer research and many improvements have been developed in the past few years [72-74]. It has high reliability and reproducibility but fluid volume is limited and the method is not good for long-term culture due to difficulty in refreshing the culture medium [58, 75].

In scaffold based cultures, the tumor cell suspension is usually mixed together with a hydrogel or a solid scaffold to develop a three-dimensional structure [63, 76]. Many different materials such as chitosan-alginate, collagen, Matrigel and Puramatrix hydrogel, were capable of forming such a scaffold structure [77-81]. An arguable advantage of this approach is that the scaffold could mimic ECM and better recapitulate the *in vivo* microenvironment. However, scaffold based culture also has drawbacks of batch variance, limited throughput, non-uniform spheroid size and distribution [63].

#### **4. Capturing essences of the tumor microenvironment - Complex microfluidics on-chip models**

Conventional *in vitro* tumor models have revealed much basic information about malignant cells. However, these models cannot predict tumor cell response accurately due to lack of a physiologically relevant microenvironment. On the other hand, although animal models have been used to recapitulate the human body environment, it is a time-consuming and expensive approach. In addition, the deviation in animal models caused by non-human genetic material seems impossible to be overcome. In contrast, a microfluidic tumor-on-a-chip can mimic the human body environment without the presence of foreign environmental factors. It also has the advantage of being cost-effective while maintaining a high throughput. Although it can be very challenging to fully regenerate the *in vivo* microenvironment in a microfluidic system, researchers have been able to capture some key features in the tumor to recapitulate the process of tumor growth and use it to better predict drug response.

#### **Table 1 Summary of microfluidic devices mimicking tumor vasculature**

Approaches	Media refreshing method	2D culture	3D culture
Endothelial cells monolayer	Perfusion	[82]: Primary BAOEC [83]: HDMECs, MDA-MB-231	[81]: T47D, PC9, HMVEC [84]: HUVEC, A549, T24 [85]: HUVEC, MDA-MB-231, MCF-7
Circular endothelial cells tube	Perfusion		[86]: HUVEC, HCCLM9 [87]: MDA-MB-231, TIME [88]: MDA-MB-231, HT-1080, HUVEC, HMVEC [89]: HUVECs, rat aortic SMCs, 3T3 [90]: P53LMACO1, HH [91]: HMVEC-d, HMVEC-dLy
Vascular network	Direct exchange		[92]: HUVEC, NHLFs, HL-60, U87MG [93]: HUVEC, NHLFs [94]: HUVEC, dermal fibroblast, human lung fibroblast, hPC-PL [95]: iPSC-EC [96]: fibroblast, HUVEC [97]: HUVEC
	Perfusion		[98]: primary hBM-MSCs, osteo-differentiated (OD) primary hBM-MSCs, HUVECs, MDA-MB-231 [99]: ECFC-ECs, NHLFs [100]: HUVECs [101]: HBTAEC, MCF-7, MDA-MB-231 [102]: human iPSCs (WTC11, C2A), HUAEC, HUVEC, HDLEC, NHLF


#### 4.1 Vasculature

Vasculature plays an essential role in the growth and metastasis of malignant tumors [103]. Malignant cells exchange nutrient and waste through vascular networks. Without recruiting new blood vessels, the size of a tumor is limited to a few millimeters in diameter [104]. The blood circulation system is also a key component in metastasis because many malignant cells migrate as circulating cancer cells through blood vessels [105]. Therefore, many attempts have been made to mimic blood vessels in microfluidics devices in recent years (**Table 1**), ranging from a planer layer of endothelial cells [81-85] to circular functional and perfusable vascular network consisting of various cell types [92, 98, 101].

Endothelial cells monolayer is the most direct approach to mimic blood vessel function in a microfluidic chip. This monolayer approach is very effective in applications where cylindrical vessel geometry of blood vessels is not very essential to the study, such as in the testing of drugs which prevent cancer cell migration because this method is high throughput and simple to fabricate [106]. As compared to the traditional transwell method, the monolayer design also

has the added advantage of easily generating shear stress. Shear stress helps cells arrange themselves to establish the barrier function [106]. As shown in **Figure 3a**, there are generally two different methods to construct these endothelial cells monolayer inside a microfluidic chip. One is to culture endothelial cells on a porous membrane [81-83]. As the endothelial monolayer becomes confluent, pores on the porous layer will be covered by cells. When fresh medium flows on one side of the membrane, it can then diffuse through the cellular monolayer to the other side of the membrane, mimicking *in vivo* blood perfusion. For example, a device was designed to incorporate a monolayer of human dermal blood microvascular endothelial cells (HMVEC) on a porous PDMS layer to mimic blood vessel in their drug screening platform [81]. It was shown that human non-small cell lung cancer cells (PC9) cultured in their devices had stronger drug resistance to four different apoptotic inducers than two-dimensional cultured PC9 cells. Instead of using PDMS monolayer for cell attachment, the other approach employs the use of hydrogels [84, 85]. In that approach, the hydrogel not only works as a scaffold for the growth of endothelial cells monolayer but also serves a function of mimicking the ECM for tumor spheroid formation.

More complex devices incorporating the tubular structure of blood vessels generally fall into two categories depending on whether the endothelial cells grow on a circular scaffold or in a cylindrical hydrogel channel (**Figure 3b**). In the former, endothelial cells or multiple types of cells are grown on a vessel-like scaffold and implanted. The resultant artificial blood vessel is then implanted into the microfluidic device. Although fabrication of the device is quite tedious, the artificial blood vessels generated by this method have relatively high mechanical strength and look like real blood vessels [86]. In one such example, an artificial blood vessel was constructed by growing human umbilical vein endothelial cells (HUVECs) in a tubular scaffold made of cellulose and collagen. By implanting three such vessels in one chip and culturing HCCLM9 cancer cells in between, it was shown that the endothelial monolayer and pulse flow could significantly delay tumor migration [86]. The other class of devices incorporating circular endothelial cell tube involves growing cells on the inner surface of a cylindrical hydrogel channel [87-91]. This method can effectively build a circular endothelial cell tube in a microfluidic device, but the co-cultured cancer cells must be fixed in the hydrogel first before construction of the endothelial cellular tube can begin. One example is a study of human breast cancer cell intravasation and extravasation in an artificial microvessel platform [88]. Human breast carcinoma cells MDA-MB-231 adenocarcinoma and HT-1080 fibrosarcoma cells were first cultured in a collagen hydrogel. A cylindrical channel was then drilled in the hydrogel using a metal rod. HUVECs were injected into the channel and gradually grown into a circular endothelial cell layer. In this study, the migration speed of cancer cells in the ECM was shown to be slower than that in ECM/vessel interface and predefined matrix tracks.



**Figure 3** Microfluidic device mimicking blood vessels using (a) endothelial cells monolayer, (b) circular endothelial cells tube and (c) functional vascular network

Different from the previous two types of devices where the artificial blood vessel is formed on a well-defined surface, some devices prompt endothelial cells to sprout in the hydrogel to develop an irregular vascular network to mimic *in vivo* capillary vessel networks (**Figure 3c**). The blood vessels developed in this type of devices are cross-linked and perfusable, closely recapitulating the *in vivo* blood flow conditions [94-97, 107]. This is necessary for studies which require the crosslinking structure of the vascular network or when angiogenesis inhibitors are involved [92, 93, 97-102]. For example, fibroblasts and HUVEVs were used to generate a vascular network in fibrinogen gel in a microfluidic chip [96]. By using this device, it was found that high-density lipoproteins exhibit a bi-phasic effect on angiogenic sprout growth and inhibit TNF- $\alpha$  stimulated angiogenesis. In another example, human breast cancer cell MDA-MB-231 suspension was flowed into the vascular network to model the extravasation process of cancer cells [98]. By blocking A3 adenosine receptors, cancer cells were observed to have a reduced extravasation rate. Through this, it was shown that adenosine played an important role in promoting tumor cells extravasation.

The level of complexity increases as one progress from the use of endothelial cells monolayer to circular endothelial cells tube and to the functional vascular network. The more complicated devices are, the closer a representative of *in vivo* conditions can be achieved albeit with a lower throughput and becoming harder to operate. In recent years, techniques which can overcome the abnormal vasculature in the tumor, such as nanoparticle drug delivery and drugs normalizing vascular network, were shown to be able to greatly improve anti-cancer treatment [108-113]. For example, simultaneous Tie2 activation and Ang2 inhibition in mice was shown to normalize vasculature. This halved the lung tumor growth rate and extended survival time by more than 20% [109]. As such, the development of a more comprehensive microfluidic tumor model with better-mimicked vasculature will allow *in vitro* fast screening of such treatment and greatly contribute to the development of anti-cancer drugs.


## 4.2 Coculture

Many different non-neoplastic cells exist in the tumor microenvironment and interact with tumor cells. Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120]. Endothelial cells are one of the major components of blood vessels and play an important role in tumor angiogenesis [121]. Its interplay with malignant cells is also key to cancer metastasis [122]. Different from normal fibroblasts, cancer-associated fibroblasts proliferate faster, produce more extracellular matrix and secrete unique cytokine, which significantly enhances carcinogenesis [123, 124]. Immune cells were shown to both enhance and inhibit malignant cells proliferation, migration, and metastasis [125-128]. Therefore, mimicking cell-cell interactions is very necessary for the design of a comprehensive *in vitro* tumor model. Current microfluidic devices capable of culturing multiple cell types can be divided into two categories, mixed co-culture system and separate co-culture system [129, 130].

Mixed co-culture microfluidic devices mix different cell types and culture them inside one single chamber [131-138] (**Figure 4a**). Although this method can better recapitulate heterogeneous cell growth environment in the tumor, it can be quite challenging to distinguish different cell types in monitoring cellular behavior in such devices, especially when one is observing the activities of more than two cell types. A typical method to identify certain cell type in such a system is to use a different fluorescent label. However, due to the concern of cross-talking between fluorescent signals, no more than 4 fluorescent dyes are usually used simultaneously on a single device. This technique was demonstrated in a recent publication where lysed human blood was cultured in a microwell device to conduct drug screening [135]. CD45-allophycocyanin was used to distinguish WBCs from putative CTCs and viability of putative CTCs was assessed by using calcein-AM/EtBr. Formation of cell clusters in the microwells was shown to be inversely correlated with increased drug concentration and therapeutic treatment and this liquid biopsy technique can potentially be used to develop personalized medicine.

Instead of simultaneously culturing various cell types in the same chamber, a separate co-culture system grows each cell type in a separate chamber and all the cell-cell interaction is achieved by substance diffusion through the culture media between individual culture chambers [131, 139-148] (**Figure 4b**). For example, cancer-associated fibroblasts (CAFs) and NSCLC cells were co-cultured in separate chambers connecting by a fluid channel and cell behavior was observed under the microscope [143]. By using this microfluidic device, it was shown that CAFs might promote NSCLC cell invasion by up-regulation of GRP78 expression. As compared to a mixed co-culture, a separate co-culture can easily distinguish the different cell types cultured in the device without fluorescent staining. However, the main drawback is

that it is not able to mimic certain cell-cell interactions which cannot be transmitted through culture media such as the ECM interaction generated by fibroblasts and the immune response from WBCs.



**Figure 4 Microfluidic devices mimicking heterogeneous cell types and elevated IFP in tumor microenvironment** using the approach of (a) mixed co-culture, (b) separate co-culture, (c) elevated IFP & shear stress and (d) elevated IFP.

### 4.3 Shear Stress

Due to the presence of interstitial flow in tumors, there is a corresponding fluid shear stress with a magnitude of approximately  $0.1 \text{ dyn cm}^{-2}$  [149]. Although this shear stress is very small when compared with the intravascular shear stress, it can still stimulate some oncogenic signaling pathways on cancer cells [150] as well as upregulate TGF $\beta$  and activate fibroblast contraction to stiffen the ECM [151]. In addition, this shear stress can also prompt vascular angiogenesis against the direction of interstitial flow [152]. Therefore, many *in vitro* researches have been conducted to mimic and investigate the influence of shear stress on tumor cells.

All current microfluidic studies generate the fluid shear stress by applying a continuous flow of culture medium in direct contact with target cells (Table 2). This flow is usually generated by a peristaltic pump [153], a syringe pump [154] or a gravitational force arising from the height difference between fluids at the inlet and outlet of the device [155]. Associated shear stress value is then estimated using numerical simulation software to make sure it is physiologically relevant. A significant difference of target cell behavior could be observed in the presence of shear stress. For example, a microfluidic device employing a straight channel design with a syringe pump generated medium flow studied the response of ovarian cancer cell spheroids to shear stress [156]. It was found that fluid shear stress could prompt ovarian cancer cell dissemination, enrich cancer stem cell population as well as enhance tumor's chemoresistance to anti-cancer drugs.

Almost all current microfluidic devices incorporating fluid flow can generate a shear stress with physiologically relevant value and can demonstrate the impact of shear stress in cultured tumor cells *in vitro* [157-160]. In current microfluidic models culturing three-dimensional tumors, fluid only flows around tumor spheroids and the quantified shear stress value is the shear stress on the outer surface of the tumor. This is, however, still different from the actual situation in the human body where shear stresses also exist inside the tumor [161].

**Table 2 Summary of microfluidic co-culture systems and chips with mimicked shear stress or IFP**

Mimic approach	Media exchange	2D culture	3D culture
Mixed co-culture	Direct exchange	[137]: Mouse fibroblast, natural killer cells	[162]: HepG2, 3T3, 4T1 [132]: MCF-7, HUVEC, NHF, RG2, H35 [135, 163]: MCF-7, Blood samples from breast cancer patients [134]: H1650, A549, cancer-associated fibroblasts, blood samples from early lung cancer patients
	Perfusion		[131]: HepG2, 4T1 [133]: SPCA-1, HFL1, cells from the fresh lung cancer tissues [136]: HMT-3522, HMF, breast DCIS [157]: ECFC-ECs, NHLFs [138]: Human pulmonary microvascular endothelial cells, NCI-H441
Separate co-culture	Direct exchange	[142]: HS5, HuH7 [145]: SKBR3, BT474, ThP1, HS5, MCF7 [147]: PBMC, MDA-MB-231 [164]: primary mouse spleen cells, B16-F10	[162]: HepG2, 3T3, 4T1 [139]: HT-29, BJ [140]: mouse smooth muscle precursor cells, hMVECs, MTLn3, MDA-MB-231 [141]: HCT116, primary rat liver microtissues [143]: A549, SPCA-1, WI38 [144]: MDA-MB-231, RAW 264
	Perfusion	[146]: T24, Raw 264.7, BJ-5Ta, HUVECs	[131]: HepG2, 4T1 [157]: ECFC-ECs, NHLFs
Shear stress	Perfusion	[158]: LS174T, Colo205, THP-1, HL-60 [153]: HCT116 [159]: JH-EsoAd1 [160]: HEK 293T, PANC-1, A549, HT-29 [165]: patient-derived xenograft with lung, melanoma and bladder cancers [155]: 22Rv1, PC3, TOV112D, OV90, tumor tissue from patient with benign prostatic hyperplasia	[154]: MDA-MB-231 [157]: ECFC-ECs, NHLFs [156]: SKOV-3
IFP	Direct exchange	[166]: A549, primary murine AEC	[167]: MDA-MB-231, PC-3



	Perfusion		[168]: MDA-MB-231 [169]: MDA-MB-231
--	-----------	--	--

#### 4.4 Pressure

Elevated extracellular stresses have been observed in many tumors [170-178]. It enhances tumor cell proliferation and builds up a transport barrier to drug delivery, greatly lowering the efficacy of anticancer drugs and therapies. Extracellular stresses have two components, namely solid stress (SS) and interstitial fluid pressure (IFP). Abnormal SS is developed by the unregulated growth of tumorigenic cells and is transmitted by the extracellular matrix [179]. In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, compromise immune cells ability to kill cancerous cells or even turn macrophages to tumor-friendly cells, thereby enhancing the metastatic potential of cancer cells [180-184]. On the other hand, the IFP is a fluid related pressure, which includes the interstitial-fluid osmotic pressure and interstitial-fluid hydrodynamic pressure. It is usually close to zero in normal tissue. However, due to the impairment of blood and lymph vessels in a tumor, the IFP could rise up to more than 30mmHg at the center and drop drastically to the normal value at the periphery of a tumor [185]. The uniformly elevated IFP in tumor center is responsible for inhibiting drug delivery [172, 178, 186] while the steep pressure gradients at the periphery favors tumor growth and metastasis [154, 187-190].

A few *in vitro* models have been used to show the effect of SS on malignant cells proliferation, growth, and migration [180, 191, 192]. However, no microfluidic studies investigating the effect of SS on tumor cells have been reported until now. There are some microfluidic devices involving SS but stretching is usually the focus rather than compression. For example, the alveolar morphological and viability differences were studied using a microfluidic system in response to a combination of fluid and solid mechanical stress [166]. In this study, human alveolar epithelial cells A549 and primary murine alveolar epithelial cells were cultured on a deformable membrane. The solid mechanical stresses were then generated by stretching and release of the membrane with alveoli. The authors were able to conclude that stretching could prompt cell detachment from culture surface from that study.

As compared to SS, the impact of interstitial pressure on tumors is better studied using microfluidics. Most research is focused on how IFP prompts cancer cells migration and metastasis [157, 167-169]. Although many current microfluidic devices have conducted research on the effect of IFP on tumor cells, they inadvertently mixed up an elevated IFP with fluid shear stress when a pressure-driven fluid flow is used (**Figure 4c**). For example, a microfluidic platform utilized external media reservoirs to investigate the IFP gradient's influence on collagen-embedded human breast cancer cell line, MDA-MB-231 [168]. The pressure gradient was found out to induce cell adhesion activation, cell polarization along flow direction and migration towards regions with higher pressures. Instead of using external fluid reservoirs to generate pressure, another study utilized a microfluidic device which integrated a gasket to generate fluid pressure. The device was then used to study the molecular mechanism behind pressure induced tumor cell invasion in microfluidic tumor models [167].

All the present approaches that mimic IFP have an associated shear stress due to the presence of significant fluid flow. As such, it is hard to identify the effect of IFP on tumor alone. Therefore, mimicking static fluid pressure is key to understanding the role of IFP in drug resistance of tumor and whether it is necessary to be recapitulated in an *in vitro* drug screening platform (**Figure 4d**). Hence, more research needs to be done on tumor-on-a-chip devices.

#### 4.5 Chemical and oxygen gradient

Many recent microfluidic devices were utilized to generate chemical or oxygen gradient in cancer research because chemical and oxygen concentrations have also been shown to greatly affect cancer progression and therapeutic efficacy [193, 194]. Chemical gradients play an important role in tumor cell invasion of metastatic cancer [195, 196] as it significantly directs the migration and differentiation of tumor cells. Hypoxic environment, on the other hand, is known to reduce cytotoxicity of many anticancer drugs, affect angiogenesis, promote metastasis and alter the metabolic activity of cancer cells [183, 197].

Microfluidic devices usually generate chemical gradient either by diffusion or convection [193]. Diffusion-based devices produce a continuous concentration gradient by allowing controlled diffusion of chemicals through a fluid or gel chamber [198-201]. By observing cell behavior in these devices, it was found that different types of cancer cells may react differently to the same chemical stimuli. This dynamic response was regulated by the  $\beta$ -catenin dependent Wnt signaling pathway [202]. Most convection-based devices are gradient generators in which several specific chemical concentrations are generated by mixing the different amount of fluid. [203-205] These are widely used in many drug screening systems to prepare drug gradients [135, 206]. There have also been some interesting microfluidic devices which adopt alternative approaches to generate these chemical gradients. For example, a thread network was shown to allow cell growth with different chemical concentrations by absorbing solutions of high and low chemical concentrations [207]. Electric fields can also be used to modulate the chemical gradient in a microfluidic device and this feature may be easily incorporated into existing devices [208].

There is usually a hypoxic core of solid tumors due to the abnormal vascular network and high cell density. A hypoxic environment can be easily incorporated into most existing systems by using a hypoxic incubator or a hypoxic workstation [194]. However, they are not able to generate oxygen gradient with spatial controls. Spatial control of oxygen concentration, which allows for the study of cancer cells respond to different oxygen levels, is important for it can reproduce oxygen distribution seen in actual tumors. To address this, many microfluidic systems with oxygen controls were developed [209]. Most of them control the oxygen levels in culture chambers and can be categorized into three groups; introducing oxygen scavenging chemicals [210, 211], gas supply channels adjacent to the cell chamber [212] and oxygen impermeable materials [213, 214]. Different from these engineering approaches, some recent works adopted 3D tissue structures to reconstitute the oxygen gradient in the tumor [215, 216]. They rebuilt largely *in vitro* 3D tumor tissues and were able to generate a hypoxic environment in the inner core, which greatly recapitulated *in vivo* spatial oxygen distribution. In a very interesting study, cell layers were wrapped like a movie strip to generate a 200um-thick 3D tissue which allowed spatial analysis of metabolites at different depths [216]. They demonstrated the change in 88 metabolites during cellular adaptation to hypoxia gradient and found that cell metabolism was deregulated in the absence of HIF.

Current microfluidic devices are capable of recapitulating *in vivo* chemical and oxygen gradient independently. However, more studies should be done to simultaneously incorporate both features to better mimic actual tumor microenvironment and predict drug response [210, 216].

#### 5. Future directions

As discussed, current microfluidic tumor models have achieved much in showing the significance of incorporating the vascular system, co-culture with physiologically relevant cell types and mimicking elevated interstitial fluid pressures as well as shear stresses. However, the

artificial microenvironment in a microfluidic chip is still a long way from the human body in terms of blood vessel architecture, cell lines used in co-culture models and functionality of mimicked elements. Fully recapitulated tumor microenvironment *in vitro* is also impossible with current technologies. Therefore, the key to developing a successful microfluidic tumor model is to select and incorporate essential features which can facilitate better drug response prediction depending on the application.

Current microfluidic tumor models with mimicked vasculature have demonstrated that tumor cells exhibit increased drug resistance when artificial blood vessels were used [81]. Human endothelial cells can sprout in hydrogels to develop a vascular network with dimensions similar to real capillaries [96, 107]. Although many *in vitro* microvessel models have been developed, none of them can actually reproduce the architecture of capillaries seen in a tumor [217, 218]. While large artificial blood vessels generated by planar or circular channels can reproduce a physiologically relevant multilayer structure, which comprises of mainly endothelial cells, vascular smooth muscle, and connective tissue, these vessels are often too big to be implanted in a vascularized tumor. On the other hand, although the artificial vascular network has similar dimensions to normal capillaries and allows coculture of multiple cell types, building a vascularized artificial tumor remains a big challenge.

By using co-culture models, it was found that cancer-associated fibroblasts may promote cancer cell invasion [143]. Commercially available cell lines are commonly used in co-culture models. However, the relevance of using immortalized cells for biological studies is questionable with issues of mutation and contamination [219, 220]. Some microfluidic works have already demonstrated the feasibility of conducting patients' cell culture in microfluidic devices [133-135, 163]. More of such studies should be carried out to facilitate the development of better cancer therapeutic strategies and personalized medicine.

Some elements among the *in vivo* microenvironments such as IFP and shear stress have been mimicked in microfluidic devices, but their full functionality has not been reproduced yet. For example, current approaches with an elevated pressure chamber do not have a blood vessel component and the magnitude of pressure is less than 10% of actual IPF *in vivo* [166-169]. Another example is the culture of patient-derived tumor tissue [155, 165]. Due to the direct use of tumor tissue, this approach includes many key components in tumor such as heterogeneous cell types and abnormal blood vessel networks. However, nutrients and drugs are not delivered through the vascular network in these studies, which compromise the prediction of drug response in these models. In addition, the various types of cells in tumor tissues were all treated as tumor cells in these studies. This can be misleading in predicting tumor response *in vitro*. For example, the efficacy of some anticancer drugs can be overestimated when these drugs are able to kill non-tumor cells in the tumor tissue because the drug efficacy is assessed based on the general cell viability of the whole tumor.

## **6. Conclusion**

Cell sources used in most *in vitro* tumor models described are cell lines derived from human patients. This is due to the difficulties in culturing primary tumor cells harvested from liquid biopsy or solid tumors and the heterogeneity in utilizing clinical samples. Besides, the current gold standard to validate proposed models still involves comparing the result with animal tests. This is primarily because animal tests are much more easily approved than clinical testing on human subjects. It is inevitable that the future generation of *in vitro* tumor models will need to use primary human cells with integrated *in vivo* conditions in order to generate predictions which are physiologically more relevant.

Nevertheless, rapid progress in different aspects of tissue engineering will greatly assist the development of *in vitro* tumor models that can recapitulate various physiologically relevant *in vivo* conditions. Multiple properties of human tissue will be incorporated into more comprehensive and sophisticated systems. The advances in microfluidic tumor models will continue to help researchers achieve a better understanding of cancer biology as well as develop novel therapeutic strategies and enabling personalized treatment.

## 7. Glossary

CTC: circulating tumor cell

ECM: extracellular matrix

IFP: interstitial fluid pressure

SS: solid stress

WBC: white blood cells

22Rv1: prostate cancer tumors

3T3: mouse fibroblast

4T1: breast cancer cells

A549: lung adenocarcinoma cell line

AEC: alveolar epithelial cell

B16-F10: melanoma cell line

BAOEC: bovine aortic endothelial cells

BJ: human foreskin fibroblasts

BJ-5Ta: fibroblasts

BT474: breast cancer epithelial cell lines

Colo205: human colorectal adenocarcinoma cell line

DCIS: ductal carcinoma *in situ*

ECFC-ECs: human endothelial colony forming cell-derived endothelial cells

H1650: non-small cell lung cancer cell line

H35: rat hepatoma cells

HBM-MSCs: human bone marrow-derived mesenchymal stem cells

HBTAEC: primary human breast tumor-associated endothelial cell

HCCLM9: hepatocellular carcinoma cell line

HCT116: human colorectal carcinoma cell line

HDLEC: human dermal lymphatic endothelial cells

HDMEC: human dermal microvascular cells

HEK 293T: human embryonic kidney epithelial cell line

HepG2: human hepatocytes

HFL1: human lung fibroblast cell line

HH: bovine vascular endothelial cell

HL-60: human promyelocytic leukemia cells

HMF: human mammary fibroblasts

HMT-3522: human mammary epithelial cell line

HMVEC: human dermal blood microvascular endothelial cells

HMVEC-d: human dermal microvascular endothelial cells

HMVEC-dLy: human lymphatic microvascular endothelial cells

hPC-PL: human placental pericytes

HS5: human bone marrow stromal cell line

HT-1080: fibrosarcoma cells

HT-29: human colorectal adenocarcinoma cells

HuH7: human hepatocarcinoma cell line  
HUAEC: human umbilical arterial endothelial cells  
HUVEC: human umbilical vein endothelial cells  
JH-EsoAd1: esophageal adenocarcinoma cell line  
LS174T: human colorectal adenocarcinoma cell line  
MCF-7: human mammary epithelial cell line  
MDA-MB-231: human breast adenocarcinoma cell line  
MTLn3: mouse breast cancer cells  
NCI-H441: Human alveolar epithelial cells from lung tumor  
NHF: normal human fibroblasts  
NHLF: normal human lung fibroblast  
iPSC: induced pluripotent stem cell  
iPSC-EC: induced pluripotent stem cell-derived endothelial cell  
OV90: ovarian cancer ascites  
P53LMACO1: mouse vascular smooth muscle cell  
PANC-1: human pancreatic adenocarcinoma cell line  
PBMC: human peripheral blood mononuclear cell  
PC-3 human prostate cancer cells  
PC9: human non-small cell lung cancer cell line  
Raw 264.7: macrophages  
RG2: rat glioblastoma cells  
SMC: smooth muscle cells  
SKBR3: breast cancer epithelial cell lines  
SKOV-3: human ovarian carcinoma cell line  
SPCA-1: human non-small cell lung cancer cell line  
SW264: mouse leukemic monocyte-macrophage  
T24: human bladder cancer cells  
T47D: human ductal breast epithelial tumor cell line  
ThP1: human monocytes  
TIME: telomerase-immortalized human microvascular endothelial cell line  
TOV112D: ovarian cancer cells  
U87MG: human glioblastoma multiforme cells  
WI38: human lung fibroblast

### **Author contributions**

MLS, RHS, and BLK are involved in the writing (original draft, review/editing) and visualization of the manuscript. CTL and JH are involved in the writing (review/editing) of the manuscript. MLS, CTL, BLK, and JH are involved in the conceptualization of the manuscript.

### **Acknowledgments**

The authors would like to thank Ms. LEE Wei Ting, Melanie from the Science Communications Unit at the Mechanobiology Institute (MBI) for the illustration (Figure 2).

## References

1. WHO | Cancer. WHO, 2017.
2. Ferlay, J., et al., *Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012*. International journal of cancer, 2015. **136**(5): p. E359-86.
3. Hanahan, D. and R.A. Weinberg, *Hallmarks of cancer: The next generation*. Cell, 2011. **144**(5): p. 646-674.
4. Valastyan, S. and R.A. Weinberg, *Tumor metastasis: Molecular insights and evolving paradigms*. Cell, 2011. **147**(2): p. 275-292.
5. Weigelt, B., J.L. Peterse, and L.J. van't Veer, *Breast cancer metastasis: markers and models*. Nature Reviews Cancer, 2005. **5**(8): p. 591-602.
6. Kessenbrock, K., V. Plaks, and Z. Werb, *Matrix Metalloproteinases: Regulators of the Tumor Microenvironment*. Cell, 2010. **141**(1): p. 52-67.
7. Mantovani, A., et al., *Cancer-related inflammation*. Nature, 2008. **454**(7203): p. 436-444.
8. Joyce, J.A. and J.W. Pollard, *Microenvironmental regulation of metastasis*. Nature Reviews Cancer, 2009. **9**(4).
9. Lalonde, E., et al., *Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study*. The Lancet Oncology, 2014. **15**(13): p. 1521-1532.
10. Holohan, C., et al., *Cancer drug resistance: An evolving paradigm*. Nature Reviews Cancer, 2013. **13**(10).
11. Trédan, O., et al., *Drug resistance and the solid tumor microenvironment*. Journal of the National Cancer Institute, 2007. **99**(19): p. 1441-1454.
12. Khoo, B.L., et al., *Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment*. Science Advances, 2016. **2**(e1600274).
13. Zhang, L., et al., *The identification and characterization of breast cancer CTCs competent for brain metastasis*. Sci Transl Med, 2013. **5**(180): p. 180ra48.
14. Sleebom, J.J.F., et al., *Metastasis in context: modeling the tumor microenvironment with cancer-on-a-chip approaches*. Dis Model Mech, 2018. **11**(3).
15. Portillo-Lara, R. and N. Annabi, *Microengineered cancer-on-a-chip platforms to study the metastatic microenvironment*. Lab Chip, 2016. **16**(21): p. 4063-4081.
16. Peela, N., et al., *Advanced biomaterials and microengineering technologies to recapitulate the stepwise process of cancer metastasis*. Biomaterials, 2017. **133**: p. 176-207.
17. Balkwill, F.R., M. Capasso, and T. Hagemann, *The tumor microenvironment at a glance*. Journal of Cell Science, 2012. **125**(23): p. 5591-5596.
18. Chen, F., et al., *New horizons in tumor microenvironment biology: challenges and opportunities*. BMC Medicine, 2015. **13**(1): p. 45-45.
19. Hynes, R.O., *The Extracellular Matrix: Not Just Pretty Fibrils*. Science, 2009. **326**(5957): p. 1216-1219.
20. Lu, P., V.M. Weaver, and Z. Werb, *The extracellular matrix: A dynamic niche in cancer progression*. Journal of Cell Biology, 2012. **196**(4): p. 395-406.
21. Ozbek, S., et al., *The Evolution of Extracellular Matrix*. Molecular Biology of the Cell, 2010. **21**(24): p. 4300-4305.
22. Whittaker, C.A., et al., *The echinoderm adhesome*. Developmental Biology, 2006. **300**(1): p. 252-266.
23. Huijbers, I.J., et al., *A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion*. PLoS ONE, 2010. **5**(3): p. 1-12.
24. Kauppila, S., et al., *Aberrant type I and type III collagen gene expression in human breast cancer in vivo*. The Journal of Pathology, 1998. **186**(3): p. 262-268.
25. Zhu, G.G., et al., *Immunohistochemical study of type I collagen and type I pN-collagen in benign and malignant ovarian neoplasms*. Cancer, 1995. **75**(4): p. 1010-1017.

26. Fang, M., et al., *Collagen as a double-edged sword in tumor progression*. *Tumour Biology*, 2014. **35**(4): p. 2871-2882.
27. Marxsen, Jan H., et al., *Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF- $\alpha$ -prolyl-4-hydroxylases*. *Biochemical Journal*, 2004. **381**(Pt 3): p. 761-767.
28. Lin, C., et al., *Hypoxia induces HIF-1 $\alpha$  and VEGF expression in chondrosarcoma cells and chondrocytes*. *Journal of Orthopaedic Research*, 2004. **22**(6): p. 1175-1181.
29. Jain, R.K., *Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy*. *Science*, 2005. **307**(5706): p. 58-62.
30. Murdoch, C., *Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues*. *Blood*, 2004. **104**(8): p. 2224-2234.
31. Qian, B.-Z. and J.W. Pollard, *Macrophage Diversity Enhances Tumor Progression and Metastasis*. *Cell*, 2010. **141**(1): p. 39-51.
32. Aylon, Y. and M. Oren, *New plays in the p53 theater*. *Current Opinion in Genetics & Development*, 2011. **21**(1): p. 86-92.
33. Muller, P.A.J. and K.H. Vousden, *P53 Mutations in Cancer*. *Nature Cell Biology*, 2013. **15**(1): p. 2-8.
34. Cekanova, M. and K. Rathore, *Animal models and therapeutic molecular targets of cancer: utility and limitations*. *Drug Design, Development and Therapy*, 2014. **8**: p. 1911-1911.
35. Ellem, S.J., E.M. De-Juan-Pardo, and G.P. Risbridger, *In vitro modeling of the prostate cancer microenvironment*. *Advanced Drug Delivery Reviews*, 2014. **79**: p. 214-221.
36. Hegerfeldt, Y., et al., *Collective Cell Movement in Primary Melanoma Explants*. *Cancer Research*, 2002. **62**(7): p. 2125-2130.
37. Provenzano, P.P., et al., *Collagen reorganization at the tumor-stromal interface facilitates local invasion*. *BMC Medicine*, 2006. **4**(1): p. 38-38.
38. Swanton, C., *Intratumor Heterogeneity: Evolution through Space and Time*. *Cancer Research*, 2012. **72**(19): p. 4875-4882.
39. Fodde, R., et al., *A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors*. *Proceedings of the National Academy of Sciences of the United States of America*, 1994. **91**(19): p. 8969-8973.
40. Kersten, K., et al., *Genetically engineered mouse models in oncology research and cancer medicine*. *EMBO Molecular Medicine*, 2017. **9**(2): p. 137-153.
41. Singh, M., C.L. Murriel, and L. Johnson, *Genetically engineered mouse models: Closing the gap between preclinical data and trial outcomes*. *Cancer Research*, 2012. **72**(11): p. 2695-2700.
42. Gengenbacher, N., M. Singhal, and H.G. Augustin, *Preclinical mouse solid tumour models*. *Nature Publishing Group*, 2017. **17**(12): p. 751-765.
43. Paoloni, M. and C. Khanna, *Translation of new cancer treatments from pet dogs to humans*. *Nat Rev Cancer*, 2008. **8**(2): p. 147-156.
44. *Recognition and Alleviation of Pain in Laboratory Animals*. 2009, Washington, D.C.: National Academies Press.
45. Mak, I.W.Y., N. Evaniew, and M. Ghert, *Lost in translation: animal models and clinical trials in cancer treatment*. *American Journal of Translational Research*, 2014. **6**(2): p. 114-118.
46. Chesler, E.J., et al., *Identification and ranking of genetic and laboratory environment factors influencing a behavioral trait, thermal nociception, via computational analysis of a large data archive*. *Neuroscience & Biobehavioral Reviews*, 2002. **26**(8): p. 907-923.
47. Thiery, J.P., et al., *Epithelial-Mesenchymal Transitions in Development and Disease*. *Cell*, 2009. **139**(5): p. 871-890.
48. Mao, Y., et al., *Stromal cells in tumor microenvironment and breast cancer*. *Cancer and Metastasis Reviews*, 2013. **32**(1-2): p. 303-315.

49. Miki, Y., et al., *The advantages of co-culture over mono cell culture in simulating in vivo environment*. Journal of Steroid Biochemistry and Molecular Biology, 2012. **131**(3-5): p. 68-75.
50. De Wever, O. and M. Mareel, *Role of tissue stroma in cancer cell invasion*. The Journal of Pathology, 2003. **200**(4): p. 429-447.
51. Casbas-Hernandez, P., J.M. Fleming, and M.A. Troester, *Gene Expression Analysis of In Vitro Cocultures to Study Interactions between Breast Epithelium and Stroma*. Journal of Biomedicine and Biotechnology, 2011. **2011**: p. 1-12.
52. Horvath, P., et al., *Screening out irrelevant cell-based models of disease*. Nature Reviews Drug Discovery, 2016. **15**(11): p. 751-769.
53. Imamura, Y., et al., *Comparison of 2D-and 3D-culture models as drug-testing platforms in breast cancer*. Oncology reports, 2015. **33**(4): p. 1837-1843.
54. Cukierman, E., et al., *Taking Cell-Matrix Adhesions to the Third Dimension*. Science, 2001. **294**(5547): p. 1708-1712.
55. Gumbiner, B.M., *Cell adhesion: The molecular basis of tissue architecture and morphogenesis*. Cell, 1996. **84**(3): p. 345-357.
56. Nath, S. and G.R. Devi, *Three-dimensional culture systems in cancer research: Focus on tumor spheroid model*. Pharmacology and Therapeutics, 2016. **163**: p. 94-108.
57. Asghar, W., et al., *Engineering cancer microenvironments for in vitro 3-D tumor models*. Materials Today, 2015. **18**(10): p. 539-553.
58. Mehta, G., et al., *Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy*. Journal of Controlled Release, 2012. **164**(2): p. 192-204.
59. Hirschhaeuser, F., et al., *Test system for trifunctional antibodies in 3D MCTS culture*. Journal of biomolecular screening, 2009. **14**(8): p. 980-990.
60. Brancato, V., et al., *3D Tumor Microtissues as an In Vitro Testing Platform for Microenvironmentally-triggered Drug Delivery Systems*. Acta Biomaterialia, 2017.
61. Rodday, B., et al., *Semiautomatic growth analysis of multicellular tumor spheroids*. Journal of biomolecular screening, 2011. **16**(9): p. 1119-1124.
62. Ingram, M., et al., *Three-dimensional growth patterns of various human tumor cell lines in simulated microgravity of a NASA bioreactor*. In Vitro Cellular & Developmental Biology-Animal, 1997. **33**(6): p. 459-466.
63. Breslin, S. and L. O'Driscoll, *Three-dimensional cell culture: the missing link in drug discovery*. Drug discovery today, 2013. **18**(5): p. 240-249.
64. Barrila, J., et al., *Organotypic 3D cell culture models: using the rotating wall vessel to study host-pathogen interactions*. Nature Reviews Microbiology, 2010. **8**(11): p. 791-801.
65. Sant, S. and P.A. Johnston, *The production of 3D tumor spheroids for cancer drug discovery*. Drug Discovery Today: Technologies, 2017.
66. Fennema, E., et al., *Spheroid culture as a tool for creating 3D complex tissues*. Trends in biotechnology, 2013. **31**(2): p. 108-115.
67. Friedrich, J., et al., *Spheroid-based drug screen: considerations and practical approach*. Nat Protoc, 2009. **4**(3): p. 309-24.
68. Ivascu, A. and M. Kubbies, *Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis*. Journal of biomolecular screening, 2006. **11**(8): p. 922-932.
69. Anada, T., et al., *Three-dimensional cell culture device utilizing thin membrane deformation by decompression*. Sensors and Actuators B: Chemical, 2010. **147**(1): p. 376-379.
70. Metzger, W., et al., *The liquid overlay technique is the key to formation of co-culture spheroids consisting of primary osteoblasts, fibroblasts and endothelial cells*. Cytotherapy, 2011. **13**(8): p. 1000-1012.
71. Timmins, N.E. and L.K. Nielsen, *Generation of multicellular tumor spheroids by the hanging-drop method*. Tissue Engineering, 2007: p. 141-151.



72. Lyden, T. and S. Strohbeen, *Generation and comparative analysis of choriocarcinoma tumor organoids using a new hanging-drop culture method*. *Placenta*, 2016. **45**: p. 105.
73. Ware, M.J., et al., *Generation of homogenous three-dimensional pancreatic cancer cell spheroids using an improved hanging drop technique*. *Tissue Engineering Part C: Methods*, 2016. **22**(4): p. 312-321.
74. Hsiao, A.Y., et al., *Micro-ring structures stabilize microdroplets to enable long term spheroid culture in 384 hanging drop array plates*. *Biomedical microdevices*, 2012. **14**(2): p. 313-323.
75. Breslin, S. and L. O'Driscoll, *Three-dimensional cell culture: the missing link in drug discovery*. *Drug Discov Today*, 2013. **18**(5-6): p. 240-9.
76. Lee, G.Y., et al., *Three-dimensional culture models of normal and malignant breast epithelial cells*. *Nature methods*, 2007. **4**(4): p. 359-365.
77. Kievit, F.M., et al., *Chitosan–alginate 3D scaffolds as a mimic of the glioma tumor microenvironment*. *Biomaterials*, 2010. **31**(22): p. 5903-5910.
78. Wang, J.-Z., et al., *Developing multi-cellular tumor spheroid model (MCTS) in the chitosan/collagen/alginate (CCA) fibrous scaffold for anticancer drug screening*. *Materials Science and Engineering: C*, 2016. **62**: p. 215-225.
79. Benton, G., et al., *Matrigel: From discovery and ECM mimicry to assays and models for cancer research*. *Advanced drug delivery reviews*, 2014. **79**: p. 3-18.
80. Sodunke, T.R., et al., *Micropatterns of Matrigel for three-dimensional epithelial cultures*. *Biomaterials*, 2007. **28**(27): p. 4006-4016.
81. Dereli-Korkut, Z., et al., *Three dimensional microfluidic cell arrays for ex vivo drug screening with mimicked vascular flow*. *Analytical Chemistry*, 2014. **86**(6): p. 2997-3004.
82. Thomas, A., et al., *Biomimetic channel modeling local vascular dynamics of pro-inflammatory endothelial changes*. *Biomicrofluidics*, 2016. **10**(1): p. 014101.
83. Song, J.W., et al., *Microfluidic endothelium for studying the intravascular adhesion of metastatic breast cancer cells*. *PLoS one*, 2009. **4**(6): p. e5756.
84. Bai, J., et al., *Identification of drugs as single agents or in combination to prevent carcinoma dissemination in a microfluidic 3D environment*. *Oncotarget*, 2015. **6**(34): p. 36603.
85. Riahi, R., et al., *A microfluidic model for organ-specific extravasation of circulating tumor cells*. *Biomicrofluidics*, 2014. **8**(2): p. 024103.
86. Wang, X.-Y., et al., *An artificial blood vessel implanted three-dimensional microsystem for modeling transvascular migration of tumor cells*. *Lab on a Chip*, 2015. **15**(4): p. 1178-1187.
87. Buchanan, C.F., et al., *Flow shear stress regulates endothelial barrier function and expression of angiogenic factors in a 3D microfluidic tumor vascular model*. *Cell adhesion & migration*, 2014. **8**(5): p. 517-24.
88. Wong, A.D. and P.C. Searson, *Live-cell imaging of invasion and intravasation in an artificial microvessel platform*. *Cancer research*, 2014. **74**(17): p. 4937-45.
89. Hasan, A., et al., *A multilayered microfluidic blood vessel-like structure*. *Biomedical microdevices*, 2015. **17**(5): p. 88.
90. Kinoshita, K., et al., *Fabrication of multilayered vascular tissues using microfluidic agarose hydrogel platforms*. *Biotechnol J*, 2016. **11**(11): p. 1415-1423.
91. Sato, M., et al., *Microcirculation-on-a-Chip: A Microfluidic Platform for Assaying Blood- and Lymphatic-Vessel Permeability*. *PLoS One*, 2015. **10**(9): p. e0137301.
92. Kim, S., et al., *Engineering of functional, perfusable 3D microvascular networks on a chip*. *Lab on a Chip*, 2013. **13**(8): p. 1489-500.
93. Park, Y.C., et al., *Microvessels-on-a-Chip to Assess Targeted Ultrasound-Assisted Drug Delivery*. *ACS applied materials & interfaces*, 2016. **8**(46): p. 31541-31549.
94. Kim, J., et al., *Engineering of a Biomimetic Pericyte-Covered 3D Microvascular Network*. *PLoS One*, 2015. **10**(7): p. e0133880.
95. Belair, D.G., et al., *Human vascular tissue models formed from human induced pluripotent stem cell derived endothelial cells*. *Stem Cell Reviews and Reports*, 2015. **11**(3): p. 511-525.

96. Ahn, J., et al., *Probing the effect of bioinspired nanomaterials on angiogenic sprouting using a microengineered vascular system*. IEEE Transactions on Nanotechnology, 2017: p. 1-1.
97. Del Amo, C., et al., *Quantification of angiogenic sprouting under different growth factors in a microfluidic platform*. J Biomech, 2016. **49**(8): p. 1340-1346.
98. Jeon, J.S., et al., *Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation*. Proceedings of the National Academy of Sciences, 2015. **112**(1): p. 214-219.
99. Hsu, Y.-H., et al., *A microfluidic platform for generating large-scale nearly identical human microphysiological vascularized tissue arrays*. Lab on a Chip, 2013. **13**(15): p. 2990-2998.
100. Kim, C., et al., *A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs*. Lab on a Chip, 2015. **15**(1): p. 301-10.
101. Tang, Y., et al., *A Biomimetic Microfluidic Tumor Microenvironment Platform Mimicking the EPR Effect for Rapid Screening of Drug Delivery Systems*. Sci Rep, 2017. **7**(1): p. 9359.
102. Kurokawa, Y.K., et al., *Human Induced Pluripotent Stem Cell-Derived Endothelial Cells for Three-Dimensional Microphysiological Systems*. Tissue Eng Part C Methods, 2017. **23**(8): p. 474-484.
103. Junttila, M.R. and F.J. de Sauvage, *Influence of tumour micro-environment heterogeneity on therapeutic response*. Nature, 2013. **501**(7467): p. 346-354.
104. Folkman, J., *Angiogenesis in cancer, vascular, rheumatoid and other disease*. Nature medicine, 1995. **1**(1): p. 27-30.
105. Plaks, V., C.D. Koopman, and Z. Werb, *Circulating Tumor Cells*. Science, 2013. **341**(6151): p. 1186.
106. Bogorad, M.I., et al., *Review: in vitro microvessel models*. Lab on a Chip, 2015. **15**(22): p. 4242-4255.
107. Song, H.H., K.M. Park, and S. Gerecht, *Hydrogels to model 3D in vitro microenvironment of tumor vascularization*. Advanced drug delivery reviews, 2014. **79-80**: p. 19-29.
108. Zhang, W.J., et al., *Tissue engineering of blood vessel*. Journal of cellular and molecular medicine, 2007. **11**(5): p. 945-57.
109. Park, J.-S., et al., *Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment*. Cancer Cell, 2016. **30**(6): p. 953-967.
110. Khawar, I.A., J.H. Kim, and H.-J. Kuh, *Improving drug delivery to solid tumors: priming the tumor microenvironment*. Journal of Controlled Release, 2015. **201**: p. 78-89.
111. Stylianopoulos, T., L.L. Munn, and R.K. Jain, *Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy*. Trends in cancer, 2018. **4**(4): p. 258-259.
112. Sun, T., et al., *Engineered nanoparticles for drug delivery in cancer therapy*. Angewandte Chemie International Edition, 2014. **53**(46): p. 12320-12364.
113. Abadeer, N.S. and C.J. Murphy, *Recent progress in cancer thermal therapy using gold nanoparticles*. The Journal of Physical Chemistry C, 2016. **120**(9): p. 4691-4716.
114. Liu, P.-F., et al., *Far from resolved: Stromal cell-based iTRAQ research of muscle-invasive bladder cancer regarding heterogeneity*. Oncology reports, 2014. **32**(4): p. 1489-1496.
115. De Palma, M. and C.E. Lewis, *Macrophage regulation of tumor responses to anticancer therapies*. Cancer cell, 2013. **23**(3): p. 277-286.
116. Hida, K., et al., *Tumour endothelial cells acquire drug resistance in a tumour microenvironment*. Journal of biochemistry, 2013. **153**(3): p. 243-249.
117. Straussman, R., et al., *Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion*. Nature, 2012. **487**(7408): p. 500-504.
118. Seguin, L., et al., *Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance*. Trends in cell biology, 2015. **25**(4): p. 234-240.

119. Di, C. and Y. Zhao, *Multiple drug resistance due to resistance to stem cells and stem cell treatment progress in cancer*. Experimental and therapeutic medicine, 2015. **9**(2): p. 289-293.
120. Easwaran, H., H.-C. Tsai, and S.B. Baylin, *Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance*. Molecular cell, 2014. **54**(5): p. 716-727.
121. Ferrara, N. and R.S. Kerbel, *Angiogenesis as a therapeutic target*. Nature, 2005. **438**(7070): p. 967-974.
122. Reymond, N., B.B. d'Agua, and A.J. Ridley, *Crossing the endothelial barrier during metastasis*. Nature Reviews Cancer, 2013. **13**(12): p. 858-870.
123. Orimo, A., et al., *Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion*. Cell, 2005. **121**(3): p. 335-348.
124. Polanska, U.M. and A. Orimo, *Carcinoma - associated fibroblasts: Non - neoplastic tumour - promoting mesenchymal cells*. Journal of cellular physiology, 2013. **228**(8): p. 1651-1657.
125. Motz, G.T. and G. Coukos, *The parallel lives of angiogenesis and immunosuppression: cancer and other tales*. Nature Reviews Immunology, 2011. **11**(10): p. 702-711.
126. Nelson, B.H., *CD20+ B cells: the other tumor-infiltrating lymphocytes*. The Journal of Immunology, 2010. **185**(9): p. 4977-4982.
127. Ma, C., et al., *A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells*. Nature medicine, 2011. **17**(6): p. 738.
128. Vacchelli, E., et al., *Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1*. Science, 2015. **350**(6263): p. 972-8.
129. Vu, T.Q., R.M.B. de Castro, and L. Qin, *Bridging the gap: microfluidic devices for short and long distance cell-cell communication*. Lab on a Chip, 2017. **17**(6): p. 1009-1023.
130. Benam, K.H., et al., *Engineered in vitro disease models*. Annual Review of Pathology: Mechanisms of Disease, 2015. **10**: p. 195-262.
131. Trietsch, S.J., et al., *Microfluidic titer plate for stratified 3D cell culture*. Lab on a Chip, 2013. **13**(18): p. 3548-3554.
132. Napolitano, A., et al., *Scaffold-free three-dimensional cell culture utilizing micromolded nonadhesive hydrogels*. BioTechniques, 2007. **43**(4): p. 494-500.
133. Xu, Z., et al., *Application of a microfluidic chip-based 3D co-culture to test drug sensitivity for individualized treatment of lung cancer*. Biomaterials, 2013. **34**(16): p. 4109-17.
134. Zhang, Z., et al., *Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model*. Oncotarget, 2014. **5**(23): p. 12383.
135. Khoo, B.L., et al., *Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment*. Science advances, 2016. **2**(7): p. e1600274.
136. Choi, Y., et al., *A microengineered pathophysiological model of early-stage breast cancer*. Lab on a Chip, 2015. **15**(16): p. 3350-7.
137. Ke, L.-Y., et al., *Cancer immunotherapy  $\mu$ -environment LabChip: taking advantage of optoelectronic tweezers*. Lab on a Chip, 2018. **18**(1): p. 106-114.
138. Huh, D., et al., *A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice*. Science translational medicine, 2012. **4**(159): p. 159ra147-159ra147.
139. Bender, B.F., A.P. Aijian, and R.L. Garrell, *Digital microfluidics for spheroid-based invasion assays*. Lab on a Chip, 2016. **16**(8): p. 1505-13.
140. Shin, Y., et al., *Microfluidic assay for simultaneous culture of multiple cell types on surfaces or within hydrogels*. Nature protocols, 2012. **7**(7): p. 1247-59.
141. Kim, J.Y., et al., *3D spherical microtissues and microfluidic technology for multi-tissue experiments and analysis*. Journal of biotechnology, 2015. **205**: p. 24-35.

142. Menon, N.V., et al., *A microfluidic co-culture system to monitor tumor-stromal interactions on a chip*. *Biomicrofluidics*, 2014. **8**(6): p. 064118.
143. Yu, T., et al., *Cancer-associated fibroblasts promote non-small cell lung cancer cell invasion by upregulation of glucose-regulated protein 78 (GRP78) expression in an integrated bionic microfluidic device*. *Oncotarget*, 2016. **7**(18): p. 25593.
144. Huang, C.P., et al., *Engineering microscale cellular niches for three-dimensional multicellular co-cultures*. *Lab on a Chip*, 2009. **9**(12): p. 1740-8.
145. Regier, M.C., et al., *Transitions from mono- to co- to tri-culture uniquely affect gene expression in breast cancer, stromal, and immune compartments*. *Biomedical microdevices*, 2016. **18**(4): p. 70.
146. Liu, P.-f., et al., *A bladder cancer microenvironment simulation system based on a microfluidic co-culture model*. *Oncotarget*, 2015. **6**(35): p. 37695-37705.
147. Biselli, E., et al., *Organs on chip approach: a tool to evaluate cancer-immune cells interactions*. *Scientific Reports*, 2017. **7**(1): p. 12737.
148. Lucarini, V., et al., *Combining type i interferons and 5-aza-2'-deoxycytidine to improve anti-tumor response against melanoma*. *Journal of Investigative Dermatology*, 2017. **137**(1): p. 159-169.
149. Mitchell, M.J. and M.R. King, *Computational and experimental models of cancer cell response to fluid shear stress*. *Frontiers in oncology*, 2013. **3**: p. 44.
150. Avvisato, C.L., et al., *Mechanical force modulates global gene expression and  $\beta$ -catenin signaling in colon cancer cells*. *J Cell Sci*, 2007. **120**(15): p. 2672-2682.
151. Swartz, M.A. and A.W. Lund, *Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity*. *Nature reviews. Cancer*, 2012. **12**(3): p. 210-9.
152. Song, J.W. and L.L. Munn, *Fluid forces control endothelial sprouting*. *Proceedings of the National Academy of Sciences*, 2011. **108**(37): p. 15342-15347.
153. Fan, R., et al., *Circulatory shear flow alters the viability and proliferation of circulating colon cancer cells*. *Scientific reports*, 2016. **6**: p. 27073.
154. Huang, Y.L., et al., *Interstitial flows promote amoeboid over mesenchymal motility of breast cancer cells revealed by a three dimensional microfluidic model*. *Integrative Biology*, 2015. **7**(11): p. 1402-1411.
155. Astolfi, M., et al., *Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy*. *Lab on a Chip*, 2016. **16**(2): p. 312-325.
156. Ip, C.K., et al., *Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress*. *Scientific reports*, 2016. **6**: p. 26788.
157. Alonzo, L.F., et al., *Microfluidic device to control interstitial flow-mediated homotypic and heterotypic cellular communication*. *Lab on a Chip*, 2015. **15**(17): p. 3521-9.
158. Oh, J., et al., *Analytical cell adhesion chromatography reveals impaired persistence of metastatic cell rolling adhesion to P-selectin*. *Journal of cell science*, 2015. **128**(20): p. 3731-43.
159. Calibasi Kocal, G., et al., *Dynamic Microenvironment Induces Phenotypic Plasticity of Esophageal Cancer Cells Under Flow*. *Scientific reports*, 2016. **6**: p. 38221.
160. Kang, T., C. Park, and B.J. Lee, *Investigation of biomimetic shear stress on cellular uptake and mechanism of polystyrene nanoparticles in various cancer cell lines*. *Archives of pharmaceutical research*, 2016. **39**(12): p. 1663-1670.
161. Chauhan, V.P., et al., *Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies*. *Annual review of chemical and biomolecular engineering*, 2011. **2**: p. 281-98.
162. Trietsch, S.J., et al., *Microfluidic titer plate for stratified 3D cell culture*. *Lab on a Chip*, 2013. **13**(18): p. 3548-54.

163. Khoo, B.L., et al., *Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device*. Nat Protoc, 2018. **13**(1): p. 34-58.
164. Businaro, L., et al., *Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment*. Lab on a Chip, 2013. **13**(2): p. 229-239.
165. Holton, A.B., et al., *Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment*. PLoS One, 2017. **12**(1): p. e0169797.
166. Douville, N.J., et al., *Combination of fluid and solid mechanical stresses contribute to cell death and detachment in a microfluidic alveolar model*. Lab on a Chip, 2011. **11**(4): p. 609-19.
167. Piotrowski-Daspit, A.S., J. Tien, and C.M. Nelson, *Interstitial fluid pressure regulates collective invasion in engineered human breast tumors via Snail, vimentin, and E-cadherin*. Integrative biology : quantitative biosciences from nano to macro, 2016. **8**(3): p. 319-31.
168. Polacheck, W.J., et al., *Mechanotransduction of fluid stresses governs 3D cell migration*. Proceedings of the National Academy of Sciences of the United States of America, 2014. **111**(7): p. 2447-52.
169. Haessler, U., et al., *Migration dynamics of breast cancer cells in a tunable 3D interstitial flow chamber*. Integrative biology : quantitative biosciences from nano to macro, 2012. **4**(4): p. 401-9.
170. Helmlinger, G., et al., *Solid stress inhibits the growth of multicellular tumor spheroids*. Nature biotechnology, 1997. **15**(8): p. 778-783.
171. Padera, T.P., et al., *Pathology: cancer cells compress intratumour vessels*. Nature, 2004. **427**(6976): p. 695-695.
172. Less, J.R., et al., *Interstitial hypertension in human breast and colorectal tumors*. Cancer research, 1992. **52**(22): p. 6371-6374.
173. Curti, B.D., et al., *Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment*. Cancer research, 1993. **53**(10): p. 2204-2207.
174. Gutmann, R., et al., *Interstitial hypertension in head and neck tumors in patients: correlation with tumor size*. Cancer research, 1992. **52**(7): p. 1993-1995.
175. Griffon-Etienne, G., et al., *Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors clinical implications*. Cancer research, 1999. **59**(15): p. 3776-3782.
176. Leu, A.J., et al., *Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation*. Cancer research, 2000. **60**(16): p. 4324-4327.
177. Nathanson, S.D. and L. Nelson, *Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma*. Annals of surgical oncology, 1994. **1**(4): p. 333-338.
178. Boucher, Y., et al., *Interstitial hypertension in superficial metastatic melanomas in humans*. Cancer research, 1991. **51**(24): p. 6691-6694.
179. Stylianopoulos, T., et al., *Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors*. Proceedings of the National Academy of Sciences, 2012. **109**(38): p. 15101-15108.
180. Demou, Z.N., *Gene expression profiles in 3D tumor analogs indicate compressive strain differentially enhances metastatic potential*. Annals of biomedical engineering, 2010. **38**(11): p. 3509-20.
181. Facciabene, A., et al., *Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells*. Nature, 2011. **475**(7355): p. 226-230.
182. Goel, S., et al., *Normalization of the vasculature for treatment of cancer and other diseases*. Physiological reviews, 2011. **91**(3): p. 1071-1121.
183. Wilson, W.R. and M.P. Hay, *Targeting hypoxia in cancer therapy*. Nature Reviews Cancer, 2011. **11**(6): p. 393.
184. Carmeliet, P. and R.K. Jain, *Molecular mechanisms and clinical applications of angiogenesis*. Nature, 2011. **473**(7347): p. 298-307.

185. Boucher, Y., L.T. Baxter, and R.K. Jain, *Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy*. *Cancer research*, 1990. **50**(15): p. 4478-4484.
186. Chauhan, V.P., et al., *Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner*. *Nature nanotechnology*, 2012. **7**(6): p. 383-388.
187. Jain, R.K., R.T. Tong, and L.L. Munn, *Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model*. *Cancer research*, 2007. **67**(6): p. 2729-2735.
188. Hofmann, M., et al., *Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model*. *Neoplasia*, 2006. **8**(2): p. 89-95.
189. Diresta, G.R., et al., *Cell proliferation of cultured human cancer cells are affected by the elevated tumor pressures that exist in vivo*. *Annals of biomedical engineering*, 2005. **33**(9): p. 1270-80.
190. Nathan, S.S., et al., *Elevated Physiologic Tumor Pressure Promotes Proliferation and Chemosensitivity in Human Osteosarcoma*. *Clinical Cancer Research*, 2005. **11**(6): p. 2389.
191. Montel, F., et al., *Isotropic stress reduces cell proliferation in tumor spheroids*. *New Journal of Physics*, 2012. **14**(5): p. 055008.
192. Tse, J.M., et al., *Mechanical compression drives cancer cells toward invasive phenotype*. *Proceedings of the National Academy of Sciences of the United States of America*, 2012. **109**(3): p. 911-6.
193. Somaweera, H., A. Ibragimov, and D. Pappas, *A review of chemical gradient systems for cell analysis*. *Anal Chim Acta*, 2016. **907**: p. 7-17.
194. Brennan, M.D., et al., *Oxygen control with microfluidics*. *Lab Chip*, 2014. **14**(22): p. 4305-18.
195. Eccles, S.A., *Targeting key steps in metastatic tumour progression*. *Current opinion in genetics & development*, 2005. **15**(1): p. 77-86.
196. Weigelt, B., J.L. Peterse, and L.J. Van't Veer, *Breast cancer metastasis: markers and models*. *Nature reviews cancer*, 2005. **5**(8): p. 591.
197. Muz, B., et al., *The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy*. *Hypoxia*, 2015. **3**: p. 83.
198. Kamei, K.-i., et al., *3D printing of soft lithography mold for rapid production of polydimethylsiloxane-based microfluidic devices for cell stimulation with concentration gradients*. *Biomedical microdevices*, 2015. **17**(2): p. 36.
199. Uzel, S.G., et al., *Simultaneous or Sequential Orthogonal Gradient Formation in a 3D Cell Culture Microfluidic Platform*. *Small*, 2016. **12**(5): p. 612-22.
200. Al-Abboodi, A., et al., *In situ generation of tunable porosity gradients in hydrogel-based scaffolds for microfluidic cell culture*. *Adv Healthc Mater*, 2014. **3**(10): p. 1655-70.
201. Del Amo, C., et al., *Quantifying 3D chemotaxis in microfluidic-based chips with step gradients of collagen hydrogel concentrations*. *Integr Biol (Camb)*, 2017. **9**(4): p. 339-349.
202. Zou, H., et al., *Microfluidic Platform for Studying Chemotaxis of Adhesive Cells Revealed a Gradient-Dependent Migration and Acceleration of Cancer Stem Cells*. *Anal Chem*, 2015. **87**(14): p. 7098-108.
203. Wang, H., et al., *A convection-driven long-range linear gradient generator with dynamic control*. *Lab Chip*, 2015. **15**(6): p. 1445-50.
204. Wang, H., et al., *A convection-driven long-range linear gradient generator with dynamic control*. *Lab on a Chip*, 2015. **15**(6): p. 1445-1450.
205. Sun, M. and S.A. Vanapalli, *Generation of chemical concentration gradients in mobile droplet arrays via fragmentation of long immiscible diluting plugs*. *Anal Chem*, 2013. **85**(4): p. 2044-8.
206. Du, G., Q. Fang, and J.M. den Toonder, *Microfluidics for cell-based high throughput screening platforms—A review*. *Analytica chimica acta*, 2016. **903**: p. 36-50.
207. Ramesan, S., et al., *Acoustically-driven thread-based tuneable gradient generators*. *Lab Chip*, 2016. **16**(15): p. 2820-8.

208. Kao, Y.C., et al., *Modulating chemotaxis of lung cancer cells by using electric fields in a microfluidic device*. *Biomicrofluidics*, 2014. **8**(2): p. 024107.
209. Byrne, M.B., et al., *Methods to study the tumor microenvironment under controlled oxygen conditions*. *Trends Biotechnol*, 2014. **32**(11): p. 556-563.
210. Chang, C.W., et al., *A polydimethylsiloxane-polycarbonate hybrid microfluidic device capable of generating perpendicular chemical and oxygen gradients for cell culture studies*. *Lab Chip*, 2014. **14**(19): p. 3762-72.
211. Wang, Z., et al., *Investigation into the hypoxia-dependent cytotoxicity of anticancer drugs under oxygen gradient in a microfluidic device*. *Microfluidics and Nanofluidics*, 2015. **19**(6): p. 1271-1279.
212. Lin, X., et al., *Oxygen-induced cell migration and on-line monitoring biomarkers modulation of cervical cancers on a microfluidic system*. *Scientific reports*, 2015. **5**: p. 9643.
213. Abaci, H.E., et al., *Design and development of microbioreactors for long-term cell culture in controlled oxygen microenvironments*. *Biomedical microdevices*, 2012. **14**(1): p. 145-152.
214. Khan, M.D.H., et al. *Microfluidic generation of physiological oxygen gradients in vitro*. in *Healthcare Innovations and Point of Care Technologies (HI-POCT), 2017 IEEE*. 2017. IEEE.
215. Patra, B., et al., *Drug testing and flow cytometry analysis on a large number of uniform sized tumor spheroids using a microfluidic device*. *Scientific reports*, 2016. **6**: p. 21061.
216. Rodenhizer, D., et al., *A three-dimensional engineered tumour for spatial snapshot analysis of cell metabolism and phenotype in hypoxic gradients*. *Nat Mater*, 2016. **15**(2): p. 227-34.
217. Nagy, J.A., et al., *Why are tumour blood vessels abnormal and why is it important to know?* *British journal of cancer*, 2009. **100**(6): p. 865-9.
218. Lafleur, M.A., M.M. Handsley, and R. Dylan, *Blood vessel structure*. *Expert Reviews in Molecular Medicine*, 2003. **5**.
219. Neimark, J., *Line of attack*. *Science*, 2015. **347**(6225): p. 938-940.
220. Irfan Maqsood, M., et al., *Immortality of cell lines: challenges and advantages of establishment*. *Cell biology international*, 2013. **37**(10): p. 1038-1045.